Pomáháme lékům pomáhat

Lékům vdechujeme reálný život

 

Publikace

Impaktované publikace

2023

5-Years Analysis of Effectivity and Toxicity of Ultra-Hypofractionated Proton Radiotherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer—A Retrospective Analysis

Jiri Kubeš, Silvia Sláviková, Pavel Vítek, Alexandra Haas, Barbora Ondrová, Kateřina Dedečková, Michal Andrlík, Martin Domanský, Kateřina Jiránková, Veronika Schlencová, Anh Harazimová, Barbora Turková, Tomáš Doležal, Sarah Falah Abass Al-Hamami and Vladimír Vondráček; Cancers 2023, 15, 4571., September 2023.

The Impact of Subclinical Hypothyroidism on the Quality of Life During Pregnancy: Mapping 5-Level Version of EQ-5D and ThyPRO-39

Tuzil Jan, Pilnackova Filkova Barbora, Watt Torquil, Jiskra Jan, Koudelkova Marcela, Novotna Eva, Tuzilova Klara, Dolezal Tomas, Bartakova Jana; Value in Health,
Volume 26, Issue 7, July 2023, Pages 1085-1097.

Employing Adalimumab in Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Real-Life Multicenter Data from the Czech Republic

Alzbeta Smetanova , Emanuel Marques , Martina Kojanova , Petr Arenberger ,
Daniela Strosova , Jorga Fialova and Monika Arenbergerova; Dermatologic Therapy,
2023 Mar 15; Article ID 3640285.

Short-term risk of periprocedural stroke relative to radial vs. femoral access: systematic review, meta-analysis, study sequential analysis and meta-regression of 2,188,047 real-world cardiac catheterizations

Tuzil J, Matejka J, Mamas AM, Dolezal T. Expert Review of Cardiovascular Therapy, 2023 Mar 7;1-12. doi: 10.1080/14779072.2023.2187378.

The impact of subclinical hypothyroidism on the quality of life during pregnancy: Mapping EQ5D 5L and ThypPRO-39.

Tuzil J, Filkova B, Watt T, et al. Value in Health. 2023 Mar 4:S1098-3015(23)00064-5. doi: 10.1016/j.jval.2023.02.015. Epub ahead of print. PMID: 36878311.

Novel approach to decision making for orphan drugs

Decker B, Mlcoch T, Pustalovova A, Dolezal T. Published online by Cambridge University Press:  07 February 2023.

Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry

Jan Hugo, Martina Kojanova, Barbora Turkova, Spyridon Gkalpakiotis on behalf of the BIOREP Study Group, Dermatology and Therapy volume 13, pages787–801 (January 2023).

 

2022

Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study

Barbora Decker, Jan Tuzil, Milan Lukas, Karin Cerna, Martin Bortlik, Barbora
Velackova, Barbora Pilnackova & Tomas Dolezal: Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study, Expert Review of Gastroenterology & Hepatology (2022)

Relationship between Patient Preferences, Attitudes to Treatment, Adherence, and Quality of Life in New Users of Teriflunomide

Štrosová D, Tužil J, Velacková Turková B, Filková Pilnáčková B, Lžičařová de Souza L, Doležalová H, Rašková M, Dufek M, Doležal T: Relationship between Patient Preferences, Attitudes to Treatment, Adherence, and Quality of Life in New Users of Teriflunomide, Pharmaceuticals 2022, Volume 15, Issue 10, 1248

Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension

Ornstová E, Tužil J, Chadimová K, Mlčoch T & Doležal T: Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension, Expert Review of Pharmacoeconomics & Outcomes Research (2022)

Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-word evidence from the Czech Republic

Turková B, Tužil J, Pilňáčková B, Doležalová H, Štrosová D, Petrů V, Seberová E & Doležal: Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-word evidence from the Czech Republic, Immunotherapy , Future Medicine (2022)

Efficacy of switches within the class of IL-17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP)

Tichy M, Kojanova M, Velackova B, Dolezal T, Spyridon Gkalpakiotis, Cetkovska P, BIOREP Study Group: Efficacy of switches within the class of IL-17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP), Dermatologic Therapy (2022)

Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry

Kojanova M, Hugo J, Velackova B, Cetkovska P, Fialova J, Dolezal T, Tichy M, Spyridon Gkalpakiotis, BIOREP Study Group: Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry, Journal of Dermatological Treatment (2022)

Real-life experience on the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic

Tánczosová M, Kojanová M, Arenbergerová M, Arenberger P, Doležal T, Štrosová D, Fialová J, Spyridon Gkalpakiotis : Real-life experience on the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic, Central European Journal of Public Health (2022)

Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry

Kojanova M, Tanczosova M, Strosova D, Cetkovska P, Fialova J, Dolezal T, Machovcova A, Spyridon Gkalpakiotis & on behalf of the BIOREP Study Group (2022): Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry, Journal of Dermatological Treatment (2022)

Přímé náklady na léčbu pacientů s nevalvulární fibrilací síní nově indikovaných k léčbě apixabanem: retrospektivně prospektivní jednoramenná kohortová studie

Štrosová D, Tužil J, Pilnáčková B, Lžičařová L, Typovská V, Doležalová H, Herold M, Doležal T, Vnitřní lékařství (2022)

 

2021

 Accession Site Does Not Influence the Risk of Stroke after Diagnostic Coronary Angiography or Intervention: Results from a Large Prospective Registry

Matějka J, Varvařovský I, Tužil J, Doležal T, Bobak M, Pospíchal J, Geier P, Vondrák J, Bláha K, Málek J, Staňková A, Bujdák J, Rozsíval V, Novotný V, Lazarák T, Plíva M, Večeřa J, Vojtíšek P, Cerebrovascular Diseases Extra (2021)

Time in remission as an alternative outcome measure for rheumatoid arthritis: a 10-year prospective study of 2618 new users of anti-TNF

Tužil J, Mlčoch T, Závada J, Svoboda M, Pavelka K, Doležal T, Rheumatology (2021)

Health-related quality of life in women with autoimmune thyroid disease during pregnancy and postpartum: systematic review including 321,850 pregnancies

Tužil J, Bartáková J, Watt T, Doležal t, Expert Review of Pharmacoeconomics & Outcomes Research, e-publication, ahead of print (2021)

Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes

Kubeš J, Haas A, Vondráček V, Andrlík M, Navrátil M, Slavíková S, Vítek P, Dědečková K, Prausová J, Ondrová B, Vinakurau Š, Grebenyuk A, Doležal T, Velacková B, Rosina J, Radiation Oncology 2021; 110(4): P1090-1097 (2021)

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

Gkalpakiotis S, Cetkovska P, Arenberger P , Dolezal T , Arenbergerova M, Velackova B , Fialova J , Kojanova M, BIOREP study group, Dermatol Ther (Heidelb) (2021)

Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic

Kojanova M, Cetkovaska P, Strosova D, Fialova J, Arenberger P, Dolezal T, Gkalpakiotis S, & The BIOREP Study Group. Dermatology and Therapy (2021)

Smoking in women with chronic vaginal discomfort is not associated with decreased abundance of Lactobacillus spp. but promotes Mobiluncus and Gardnerella spp. overgrowth: secondary analysis of trial data including microbiome analysis

Tužil J, Filková B, Malina J, Kerestes J, Doležal T. Česká gynekologie (2021)

Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex‐specific differences in psoriasis in the Czech Republic

Kojanova M, Fialova J, Cetkovska P,  Dolezal T, Lomicova I, Arenberger P, Gkalpakiotis S, the BIOREP Study Group. Dermatologic therapy (2021)

Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn’s Disease

Mlcoch T, Decker B, Dolezal T, Applied Health Economics and Health Policy 2021 (19): 593-604 (2021)

 

2020

Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe

Zemanova M, Jakopovic M, Stanic K, Łazar-Poniatowska M, Vrankar M, Rusu P, Ciuleanu T, Radosavljevic D, Bogos K, Nawrocki S,Ve spolupráci, Radiol Oncolol 2020; 54(4): 447-454 (2020)

Tea Extract Vaginal Ovule for Intermediate Flora: Randomized Blinded Vehicle-Controlled Multicenter Pilot Clinical Trial with Microbiome Analysis

Tuzil J, Filkova B, Jircikova J, Dolezalova H, Malina J, Decker B, Kerestes J, Gemerlova P, Cepicka Libalova Z, Dvorak V, Kacer V, Kosova H, Adamova Z, Dolezal T, JBAPN, Volume 10, Issue 5 (November 2020)

Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients

Fiala O, Finek J, Poprach A, Melichar B, Kopecký J, Zemanová M, Kopečková K, Mlčoch T, Doležal T, Čapková L, Buchler T, Cancers, Volume 12, Issue 4 (April 2020)

 

2019

Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry

Tužil J, Mlčoch T, Jirčíková J, Závada J, Nekvindová L, Svoboda M, Uher M, Křístková Z, Vencovský J, Pavelka K, Doležal T, Expert Opinion on Biological Therapy (2019)

Propensity Score Weighting Using Overlap Weights: A New Method Applied to Regorafenib Clinical Data and a Cost-Effectiveness Analysis

Mlcoch T, Hrnciarova T, Tuzil J, Zadak J,  Marisca M, Dolezal T, Value in Health, August (2019)

Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS

Horakova D, Rockova P, Jircikova J, Doležal T, Vachova M, Hradilek P, Valis M, Sucha J, Martinkova A, Ampapa R, Grunermelova M, Stetkarova I, Stourac P, Mares J, Dufek M, Kmetova E, Adamkova J, Hrnciarova T,  Multiple Sclerosis and Related Disorders, October (2019): 196-202

 

2018

Highly Innovative Drug Program in the Czech Republic: Description and Pharmacoeconomic Results— Cost-Effectiveness and Budget Impact Analyses

Ornstova E, Sebestianova M, Mlcoch T, Lamblova K, Dolezal T. Value in Health Regional Issues 16, September (2018): 92-98.

HTA in the Czech Republic: Still Behind

Rogalewicz V, Kubátová I, Donin G, Doležal T, Lamblová K, Bartáková J, Kneppo P World Congress on Medical Physics and Biomedical Engineering 2018 (Vol. 2). Springer Nature Singapore Pte Ltd., 2019. IFMBE Proceedings. vol. 68/2. ISSN 1680-0737. ISBN 978-981-10-9037-0.

Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic

Adenubiova E, Arenberger P, Gkalpakioti P, Arenbergerova M, Jircikova J, Dolezal T, Gkalpakiotis S. J Dermatolog Treat. 2018 Jan 17: 1-4. doi: 10.1080/09546634.2018.1425358. [Epub ahead of print].

 

2017

Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries

Kojanova M, Fialova J, Cetkovska P, Gkalpakiotis S, Jircikova J, Dolezal T, Arenberger P. BIOREP study group. Int J Dermatol. 2017 Apr; 56(4): 428-434.

New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic

Havrdova E, Kobelt G, Berg J, Capsa D, Gannedahl M, Dolezal T. European Multiple Sclerosis Platform. Mult Scler. 2017 Aug; 23 (2_suppl): 41-52.

Dietary patterns, cost and compliance with low-protein diet of phenylketonuria and other inherited metabolic diseases

Mlcoch T, Puda R, Jesina P, Lhotakova M, Sterbova S, Dolezal T. Eur J Clin Nutr. 2017 Jun 28. doi: 10.1038/ejcn.2017.102. [Epub ahead of print].

Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis

Mlcoch T, Tuzil J, Sedova L, Stolfa J, Urbanova M, Suchy D, Smrzova A, Jircikova J, Hrnciarova T, Pavelka K and Dolezal T. Patient 2017, Nov 22, doi: https://doi.org/10.1007/s40271-017-0285-1 . [Epub ahead of print].

 

2016

Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study

Mlčoch T, Klimeš J, Jirčíková J, Doležal T, Macek M et al. European Journal of Health Economics (2017): 18: 73-82. Accepted and published online in January 2016.

Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis

Mlčoch T, Šedová L, Štolfa J, Urbanová M, Suchý D, Smržová A, Jirčíková J, Pavelka K, Doležal T. Expert Review of Pharmacoeconomics & Outcomes Research 17(2): 203-211 (2017). Accepted and published online in June 2016.

The Quality of Life following allogeneic Hematopoietic Stem Cell Transplantation – a Multicenter Retrospective Study

Válková V, Jirčíková J, Trnková M, Steinerová K, Keslová P, Lánská M, Kořístek Z, Raida L, Kruntorádová K, Doležal T, Benešová K, Cetkovský P, Trněný M. Neoplasma. 2016 Jul 29; 63(5).

Cost of severe hypoglycaemia in nine European countries

Jakubczyk M, Lipka I, Pawęska J, Niewada M, Rdzanek E, Zaletel J, Ramírez de Arellano A, Doležal T, Chekorova Mitreva B, Nagy B, Petrova G, Šarić T, Yfantopoulos J, Czech M.
J Med Econ. 2016 Oct; 19(10): 973-82.

 

2015

Klinické a ekonomické přínosy nových antidiabetik v České republice

Doležal T, Kruntorádová K. Vnitřní lékařství 2015; 61 (SUppl 3): 3S50-53.

 

2014

Costs of multiple sclerosis - extrapolation of Czech data to Polish patients

Szmurło D, Fundament T, Ziobro M, Kruntorádová K, Doležal T, Głogowski C. Expert Rev Pharmacoecon Outcomes Res. 2014; 14(3): 451-458.

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis

Kruntoradova K, Klimeš J, Sedova L, Stolfa J, Doležal T, Petříková A. Value in Health Regional Issues. 2014; 4C: 100-106.

Medical and Productivity Costs of Rheumatoid Arthritis in The Czech Republic: Cost-of-Illness Study Based on Disease Severity

Klimeš J, Vocelka M, Šedová L, Doležal T, Mlčoch T, Petříková A, Vlček J. Value in Health Regional Issues 4C (2014): 75-81.

 

2013

The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008

Petříková A, Doležal T, Klimeš J, Vocelka M, Šedová L, Kolář J. Rheumatol Int. 2013; 33: 1813-1819.